Hutchmed China Ltd ADR (HCM) Stock Price, Quote & News

Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung c...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 852 2121 8200

Website: www.hutch-med.com

Address:

Cheung Kong Center, 48th floor 2 Queen's Road Central, Hong Kong, Hong Kong

briefingcom May. 21 at 12:33 PM

$HCM: HUTCHMED and Innovent Biologics (IVBIY) jointly announce NMPA Approval for TYVYT in combination with ELUNATE for the treatment of patients with locally advanced or metastatic renal cell carcinoma https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260521060509HCM&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

SuperGreenToday May. 12 at 11:11 AM

$HCM Share Price: $12.87 Contract Selected: Nov 20, 2026 $12.5 Calls Buy Zone: $3.06 – $3.78 Target Zone: $5.48 – $6.70 Potential Upside: 69% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

briefingcom Apr. 29 at 12:43 PM

$HCM: HUTCHMED announces that the New Drug Application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260429060701HCM&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

NorthStarStats Apr. 2 at 1:42 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $WAB Score 100, $NUVL Score 98, $OMER Score 98, $HCM Score 98, $ZLAB Score 98

0 · Reply

Quantumup Apr. 1 at 4:42 PM

Truist reiterated $NUVB Buy; $12 $DSNKY DSKYF $HCM BAYRY LLY RIGL Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20

1 · Reply

StocktwitsEarnings Mar. 5 at 2:40 PM

$HCM Q2 '25 Earnings Results & Recap Hutchison China MediTech reported 2025 consolidated revenue of $548.5M and net income of $456.9M, a significant increase from $37.7M in 2024, primarily driven by a divestment gain.

0 · Reply

StocktwitsEarnings Mar. 5 at 2:40 PM

$HCM Q2 '25 Earnings Results & Recap HUTCHMED reported consolidated revenue of $548.5M and net income attributable to the company of $456.9M for 2025, resulting in basic earnings per share of $0.53.

0 · Reply

BillionerOfKing Feb. 25 at 4:31 AM

$HCM Current Stock Price: $15.00

0 · Reply

BillionerOfKing Jan. 29 at 2:08 PM

$HCM Current Stock Price: $15.20 Contracts to trade: $15 HCM Feb 20 2026 Call Entry: $1.04 Exit: $1.50 ROI: 44% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

topstockalerts Jan. 7 at 3:25 PM

HUTCHMED announced that its Phase III ESLIM-02 trial of sovleplenib met its primary endpoint in adults with warm autoimmune hemolytic anemia (wAIHA) in China. The study showed a durable hemoglobin response between weeks 5 and 24 in patients who had relapsed or were refractory to at least one prior standard therapy. Sovleplenib, a novel spleen tyrosine kinase inhibitor, builds on strong Phase II data that demonstrated significantly higher response rates versus placebo. wAIHA is a rare but serious autoimmune disorder with limited treatment options. Investigators noted the drug’s potential to deliver rapid and sustained hemoglobin improvements. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s regulator in the first half of 2026 and is also advancing the drug for immune thrombocytopenia, with another NDA planned in the same timeframe. $HCM

0 · Reply

A Look at HUTCHMED (China) Ltd (HCM) After 4.3% Decline -- GF Value $13.82 vs Price $11.22

2026-05-28T21:09:08.000Z - 9 days ago

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

May 21, 2026, 8:00 PM EDT - 16 days ago

Market Cap	1.90B
Revenue (ttm)	548.51M
Net Income (ttm)	456.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	28.16
Profit Margin	83.30%
Debt to Equity Ratio	0.07

Volume	120,900
Avg Vol	46,012
Day's Range	N/A - N/A
Shares Out	174.47M
Stochastic %K	13%
Beta	0.26
Analysts	Sell
Price Target	$20.40